Gout, the most common type of inflammatory arthritis, currently affects approximately 5 million patients in United States. Based on one study, the prevalence of gout increased from 2.9 to 5.2 cases per 1000 individuals between 1990 and 1999. This CE activity will examine the disease process, inflammatory process, and hyperuricemia fundamentals of gout, including underexcretion, overproduction, cellular breakdown, and kidney stones. It will discuss lifestyle modifications, management of acute flares, and treatment of chronic gout, focusing on the role of the pharmacist in managing the disease.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Discuss the epidemiologic significance of gout and identify patient groups at risk for gout.
2. Demonstrate familiarity with the clinical presentation and diagnosis of gout.
3. Discuss genetic factors and biochemical systems that control purine production.
4. Identify pharmacologic and nonpharmacologic measures to reduce the risk of, and when necessary, treat gout flares.
5. Counsel patients and other health care providers on appropriate options, usage, possible side effects, and monitoring of various gout-related medications.
6. Recognize the role of the pharmacist in caring for patients with, or who are at risk for developing, gout.